Description

Ornipressin Acetate (POR-8) is a synthetic peptide derivative of vasopressin with high specificity toward the V1 receptor, providing potent vasoconstrictive, hemostatic, and renal-modulating effects. This highly pure compound (98.86%) is manufactured in a GMP-compliant facility, ensuring consistent quality for laboratory research applications. Ornipressin acetate exhibits significant pharmacological activity as a local vasoconstrictor, making it a valuable agent in experimental studies investigating hypotensive conditions, blood pressure modulation, renal perfusion, and hemostasis mechanisms.

Functionally, Ornipressin Acetate acts as a selective vasopressin receptor agonist, binding primarily to the V1 receptor subtype on vascular smooth muscle. This interaction triggers vasoconstriction, thereby increasing systemic vascular resistance and arterial blood pressure. Experimental studies have demonstrated that Ornipressin Acetate can effectively reverse hypotension associated with combined general and epidural anesthesia, providing a controlled model for cardiovascular research. Moreover, its antidiuretic activity and renal perfusion effects make it highly suitable for studies exploring renal hemodynamics and protective interventions in renal failure models.

This peptide exhibits dose-dependent effects in in vivo models, enhancing renal blood flow while decreasing renal vascular resistance, which provides critical insights for experimental nephrology. Additionally, Ornipressin Acetate has been utilized in hemostasis studies, where it promotes vascular contraction and platelet aggregation, demonstrating its utility in modeling surgical and trauma-induced bleeding. Its stability and solubility in acetate form further enhance its reproducibility in laboratory assays, enabling precise experimental design across multiple research disciplines, including pharmacology, physiology, and anesthesiology.

Product Specifications

Mechanism of Action & Research Applications

Ornipressin Acetate exerts its pharmacological effects through selective activation of the vasopressin V1 receptor on vascular smooth muscle cells. Upon binding, it activates phospholipase C (PLC), triggering the hydrolysis of phosphatidylinositol 4,5-bisphosphate to inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). The resultant increase in intracellular calcium induces smooth muscle contraction, leading to vasoconstriction and elevated arterial pressure. This mechanism mimics physiological vasopressin activity but with enhanced V1 receptor selectivity, which minimizes off-target effects associated with V2 receptor-mediated antidiuretic action.

In experimental cardiovascular models, Ornipressin Acetate is used to investigate mechanisms of blood pressure regulation, vascular tone, and hypotensive states induced by anesthesia or blood loss. It is also employed to simulate clinical interventions in hypotension and hemorrhagic conditions, enabling the development of novel therapeutic strategies and drug candidates.

Renal research applications include studies on renal vascular resistance, renal blood flow, and kidney-protective interventions. Ornipressin acetate’s antidiuretic and vasoconstrictive actions provide a valuable model for exploring hemodynamic regulation in renal insufficiency and acute kidney injury scenarios. Additionally, its hemostatic properties are exploited in experimental surgery and trauma studies to evaluate vascular contraction, platelet aggregation, and bleeding control mechanisms.

Further research applications extend to pharmacodynamics studies, dose-response investigations, and preclinical models of cardiovascular and renal disorders. Ornipressin Acetate’s stability and reproducibility make it ideal for long-term experiments, pharmacokinetic analyses, and comparative studies of vasopressin analogs. Its precise V1 receptor targeting allows for selective modeling of receptor-specific effects, critical in designing experiments that delineate receptor subtype contributions in complex physiological pathways.

Side Effects (For Reference in Models)

In experimental models, Ornipressin Acetate may induce transient hypertension due to potent V1 receptor-mediated vasoconstriction. Excessive doses can lead to reflex bradycardia or reduced cardiac output. Renal studies may observe decreased renal perfusion at supraphysiological concentrations, though typical experimental doses are well-tolerated. Local injection sites may show mild tissue irritation or transient vasospasm. As a research peptide, its systemic effects are limited to model organisms or in vitro systems. All studies should adhere to institutional safety protocols and standard laboratory practices.

Disclaimer

Ornipressin Acetate is intended for laboratory research purposes only. It is not for human or veterinary use, diagnostic procedures, or clinical applications. Users must follow institutional guidelines, safety protocols, and local regulations when handling this peptide.

Keywords

Ornipressin Acetate, POR-8 peptide, V1 receptor agonist, vasopressin analog, vasoconstrictor peptide, hemostatic peptide, renal perfusion peptide, laboratory research peptide, cardiovascular research peptide, experimental vasopressin analog, GMP peptide for research, antidiuretic research peptide, wholesale peptide supplier, peptide for anesthesia research, high purity Ornipressin acetate,CAS : 914453-98-8